Spots Global Cancer Trial Database for FT538 in Subjects With Advanced Hematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: FT538 in Subjects With Advanced Hematologic Malignancies
Official Title: A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
Study ID: NCT04614636
Study Description
Brief Summary: This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Colorado Blood Cancer Institute, Denver, Colorado, United States
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Washington University, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
St. David's South Austin Medical Center, Austin, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Texas Transplant Institute, San Antonio, Texas, United States
Contact Details
Name: Fate Trial Disclosure
Affiliation: Fate Therapeutics, Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
